Τόμος 15 (2001) – Τεύχος 2 – Άρθρο 2 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 15 (2001) – Issue 2 – Article 2 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

Alexandra General Hospital, Athens, Greece

Accepted for publication: 5 April 2001

pharmakonpress[at]pharmakonpress[.]gr

2.    Niebyl J.: Teratology and Drugs in Pregnancy and Lactation. In: Danforth’s, Obstetrics and Gynecology. 6^th ed. P. 273, J. B. Lippincott Company, Philadelphia, 1990

3.    Κίτσιου-Τζέλη Σ.: Τερατογόνοι Παράγοντες και Συγγενείς Ανωμαλίες. σελ. 135-160, Αθήνα, 1992

4.    Herbst A. L.: Diethylstilboestrol exposure-1984. N. Engl. J. Med. 311: 1433-1434(1984)

5.    Lee E.W., D’Alonzo G.E: Cigarette smoking, nicotine addiction and pharmacologic treatment. Arch. Intern. Med. 153: 34-48 (1993)

6.    Mueller R., Young I.: Emery’s Elements of Medical Genetics. 9^th ed. Pp. 193-204, Churchill Livingstone Inc., New York, 1995

7.    Moore K.L, Persaud T.V.N.: The Developing Human: Clinically Oriented Embryology (5^th ed.). Pp 142-173, W.B. Saunders, Philadelphia, 1993

8.    Newman G.H.: Clinical aspects of thalidomide embryopathy a continuing preoccupation. In: (Sever J.L., Brent R.L., eds) Teratogen Update. Enviromentally Induced Birth Defect Risks. Pp.1-12, Alan R Liss, New York, 1985

9.    Schardein J.L.: Chemically induced Birth Defects. Marcel Dekker Inc., New York, 1985

10.  Warkany J.: Congenital Malformations. Notes and Comments. Year Book, Medical Publishers, Chicago, 1971

11.  Lenz W.: Susceptible period for thalidomide malformations in man and monkey. Ger. Med. Mon. 13: 197 (1968)

12.  Taussing H.B.: The evils of camouflage as illustrated by thalidomide. N. Engl. J. Med. 269: 92-94 (1963)

13.  Dashe J.S., Gilstrap L.C.; Antibiotic use in pregnancy. Obstet. Gynecol. Clin. North Am. 24: 618-629 (1997)

14.  Landers D.V., Green J.R., Sweet R.L: Antibiotic use during pregnancy and the postpartum period. Clin. Obstet. Gynecol. 26: 391 (1983)

15.  Heinonen C.P., Slone D., Shapiro S.: Birth Defects and Drugs in Pregnancy. Littleton Puplishing Sciences Group, Littleton MA, 1977

16.  Wendel G.D., Stark B.J., Jamison R.B., et al.: Penicillin allergy and desensitization in serious maternal/fetal infections. N. Engl. J. Med. 312: 1229 (1985)

17.  Kafetzis D.A., Brater D.C., Fanourgakis J.E., et al.: Ceftriaxone distribution between maternal blood and fetal blood and tissues at parturition and between blood and milk postpartum. Antimicrob. Agents Chemother. 22: 870 (1983)

18.  Gonik B., Feldman S., Pickering L.K., et al.: Pharmacokinetics of cefoperazone in the parturient. Antimicrob. Agents Chemother. 30: 874 (1986)

19.  Heikkinen T., Laine K., Neuvonen P.J., Ekblad U.: The transplacental transfer of the macrolide antibiotics erythromycin, roxithromycin and azithromycin. BJOG 107: 770- 775 (2000)

20.  Weinstein A.J., Gibbs R.S., Gallagher M.: Placental transfer of clindamycin and gentamicin in term pregnancy. Obstet. Gynecol. 124: 688 (1976)

21.  American Thoracic Society: Treatment of tuberculosis and tuberculosis infection in adults and children. Am. J. Respir. Crit. Care Med. 149: 1359 (1994)

22.  Fleischman J.K., Greennberg H.E., Kanengiser L.C., et al.: Tuberculosis. Prim. Care Update Ob/Gyn. 1: 227 (1994)

23.  Snider D.E., Layde P.M., Johnson M.W., et al.: Treatment of tuberculosis during pregnancy. Am. Rev. Respir. Dis. 122: 65 (1980)

24.  Morgan I.F.K.: Metronidazole treatment in pregnancy. In: (Phillips I., Collier J., eds). Metronidazole Proceedings. Geneva, April 25-27, Academic Press, New York, 1979

25.  Simms-Cendan J.S.: Metronidazole. Prim. Care Update Ob/Gyn. 2: 153 (1996)

26.  Kantor H.I., Sutherland D.A., Leonard J.T., et al.: Effect on bilirubin metabolism in the newborn of sulfisoxazole administration to the mother, Obstet. Gynecol. 17: 494 (1961)

27.  Brumfitt W. Pursell R.: Trimethoprim/Sulfametho-xazole in the treatment of bacteriuria in women. J. Infect. Dis. 122: 657 (1973)

28.  Williams J.R., Cordie A.P., Brumfitt W., et al.: The treatment of bacteriuria in pregnant women with sulphamethoxazole and trimethoprim. Postgrad. Med. J. 45 (Supp): 71 (1969)

29.  Ben David S., Einarson T., Ben David Y. et al.: The safety of nitrofurantoin during the first trimester of pregnancy: Meta-analysis. Fund. Clin. Pharmacol. 9: 503 (1995)

30.  Powell R.D., DeGowin R.L., Alving A.S.: Nitrofurantoin induced hemolysis. J. Lab. Clin. Med. 62: 1002 (1963)

31.  Kutscher A.H., Zegarelli E.V., Toveli H.M., et al.: Discoloration of deciduous teeth induced by administration of tetracycline antepartum. Am. J. Obst. Gynecol. 98: 291 (1986)

32.  Rendle-Short T.J.: Tetracycline and teeth and bone. Lancet 1: 1188 (1962)

33.  Porter P.J., Sweeney E.A., Golan H., et al.: Controlled study of the effect of prenatal tetracycline on primary dentition. In: Antimicrobial Agents and Chemotherapy- 1965. Pp. 668, Proceedings of the 5^th Interscience Conference on Antimicrobial Agents and Chemotherapy and 4^th International Congress of Chemotherapy, Washington DC, 1965

34.  Rodondi L.C.: Quinolones, an update. The Bulletin of the Hospital Pharmacy and Drug Information Analysis Service. Pharmacy and Therapeutics Forum, University of California, San Francisco 35: 4 (1987)

35.  Christensen B.: Which antibiotics are appropriate for treating bacteriuria in pregnancy? J. Antimicrob. Chemother. (suppl)1: 29-34, 63-65 (2000)

36.  Mulvihill J.J., McKeen E.A., Rosner F., et al.: Pregnancy outcome in cancer patients. Cancer 50: 1143 (1987)

37.  Nettleton J., Long, Kuban D., et al.: Breast cancer during pregnancy: Quantifying the risk of treatment delay. Obstet. Gynecol. 87: 414 (1996)

38.  Glantz J.C.: Reproductive toxicology of alkylating agents. Obstet. Gynecol. Surv. 49: 709 (1994)

39.  Sorosky J.I., Sood A.K., Buekers T.E.: The use of chemotherapeutic agents during pregnancy. Obstet. Gynecol. Clin. North Am. 24: 591-599 (1997)

40.  Reynoso E.E., Shepherd F.A., Messner H.A. et al.: Acute leukemia during pregnancy: The Toronto Leukemia Study Group experience with long-term follow-up of children exposed in utero to chemotherapeutic agents. J. Clin. Oncol. 5: 1098 (1987)

41.  Aviles A., Diaz-Magneo J.C., Talavera A„ et al.: Growth and development children of mothers treated with chemotherapy during pregnancy: Current status of 43 children. Am. J. Hemat. 38: 243 (1991)

42.  Aviles A., Niz J.: Long- term follow-up of children born to mothers with acute leukemia during pregnancy. Med. Pediatr. Oncol. 16: 3 (1988)

43.  Malone J.M., Gershenson D.M., Creasy R.K., et al.: Endodermal sinus tumor of the ovary associated with pregnancy. Obstet. Gynecol. 68: 865 (1986)

44.  Esplin S.M., Branch W.D.: Immunosuppressive drugs and pregnancy. Obstet. Gynecol. Clin. North Am. 24: 601- 616 (1997)

45.  Ujhazy E., Balonova T., Durisova M., et al.: Teratogenicity of cyclophosphamide in New Zealand white rabbits. Neopiasma 40, 45 (1993)

46.  Kola I., Vogel R., Spielmann H.: Co-administration of ascorbic acid and cyclophosphamide to pregnant mice inhibits clastogenic activity of CPA in preimplantation murine blastocysts. Mutagenesis 4: 297 (1989)

47.  D’lncalci M., DePalo G., Semprini A.: Transplacental passage of cyclophosphamide. Cancer Treat. Rep. 8: 1681 (1982)

48.  Greenberg L., Tanaka K.: Congenital anomalies probably induced by cyclophosphamide. JAMA 188: 423 (1964)

49.  Murray F.A.: Lupus erythematosus in pregnancy. J. Obstet. Gynaecol. Br. Emp. 65: 401 (1958)

50.  Sweet D., Kinzie J.: Consequences of radiotherapy and antineoplasmatic therapy for the fetus. J. Reprod. Med. 17: 241 (1976)

51.  Kirshon B., Wasserstrum M., Willis R., et al.: Teratogenic effects of first trimester cyclophosphamide therapy. Obstet. Gynecol. 72: 462 (1988)

52.  Schardein J.L.: Cancer chemotherapeutics agents. In: (Schardein J.L., ed.) Chemically induced Birth Defects. 2nd ed., P. 457, Marcel Dekker Inc, New York, 1993

53.  Turchi J.J., Villasis C.: Anthracyclines in the treatment of malignancy in pregnancy. Cancer 61: 435 (1988)

54.  Gililland J., Weinstein L.: The effects of cancer therapeutics agents on the developing fetus. Obstet. Gynecol. Surv. 38: 6 (1983)

55.  Shapira D.V., Chudley A.E.: Successful pregnancy following continuous treatment with combination chemo-therapy before conception and throughout pregnancy. Cancer 54: 800 (1983)

56.  Doll R.C., Ringenberg Q.S., Yarbo J.W.: Management of cancer during pregnancy. Arch. Intern. Med. 14: 2058 (1989)

57.  Kozlowski R.D., Steinbrunner J.V., Mackenzie A.H., et al.: Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am. J, Med. 88: 59 (1990)

58.  Stephens J.D., Golbus M.S., Miller T.R., et al.: Multiple congenital anomalies in a fetus exposed to 5-flurouracil during the first trimester. Am. J. Obstet. Gynecol. 137: 746 (1980)

59.  Caligiuri M.A., Mayer R.J.: Pregnancy and leukemia. Semin. Oncol. 18: 388 (1989)

60.  Zemlickis D., Lishner M., Degendorfer P., et al.: Fetal outcome after in utero exposure to cancer chemotherapy. Arch. Intern. Med. 152: 573 (1992)

61.  Williams S.F., Schilsky R.L.: Antineoplastic drugs ad-ministered during pregnancy. Semin. Oncol. 27: 618-622 (2000)

62.  Anderson P.: Drug use during breast-feeding. Clin. Pharm. 18: 594 (1991)

63.  Levy G., Garrettson L.: Kinetics of salicylate elimination by newborn infants of mothers who ingested aspirin before delivery. Pediatrics 58: 202 (1974)

64.  Schoenfeld A., Bar Y., Mertob P., et al.: NSAIDs: Maternal and fetal considerations. Am. J. Reprod. Immunol. 25: 141 (1992)

65.  Collins E., Turner G.: Maternal effects of regular salicylate ingestion in pregnancy. Lancet 2: 335 (1975)

66.  Cote C., Menwissen H., Rickering R.: Effects on the neonate of prednisone and azathioprine administered to the mother during pregnancy. J. Pediatr. 85: 324 (1974)

67.  Cowchock F., Reese E., Balaban D., et al.: Repeated fetal losses associated with antiphospholipid antibodies: A collaborative randomized trial comparing prednisone with low dose heparin treatment. Am. J. Obstet. Gynecol. 275: 804(1992)

68.  Scone D., Heinonen O., Kaufman D., et al: Aspirin and congenital malformations. Lancet 1: 1373 (1976)

69.  Weder M., Mitchell A., Shapiro S.: The relation of aspirin use during the first trimester of pregnancy to congenital cardiac defects. N. Engl. J. Med. 321: 1169 (1984)

70.  Stuart J.J., Gross S.J., Elrad H., et al.: Effects of ace- tylsalicylic acid ingestion on maternal and neonatal hemostasis. N. Engl. J. Med. 307: 909 (1982)

71.  Armenti V., Ahlswede K., Ahlswede B., et al.: National transplantation pregnancy registry: Outcomes of 154 pregnancies in cyclophosphamide-treated female kidney trans-plant recipients. Transplantation 57: 502 (1994)

72.  Goldenberg R., Davis R., Baker R.: Indomethacin induced oligohydramnios. Am. J. Obst. Gynecol. 160: 1196 (1989)

73.  Kirshon B., Moïse K., Wasserstrum M.: Influence of short term indomethacin therapy on fetal urine output. Obstet. Gynecol. 72: 51 (1988)

74.  Norton M.E.t Merrill J., Cooper B.A.B., et al.: Neonatal complications after the administration of indomethacin for preterm labor. N. Engl. J. Med. 329: 1602 (1993)

75.  Torfs C., Katz E., Bateson T., et al.: Maternal medications and environmental exposure as risk factors for gastroschisis. Teratology 54: 84 (1996)

76.  Weinblatt M.t Kaplan H., Germain B., et al.: Methotrexate in rheumatoid arthritis: A five year prospective multi-center study. Arthritis Rheum. 37: 1492 (1994)

77.  Kaplan B., Restaino I., Raval D., et al.: Renal failure in the neonate associated with in utero exposure to non-steroidal anti-inflammatory agents. Pediatr. Nephrol a. 700 (1994)

78.  Ostensen M., Villiger P.M.: Nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus. Lupus 9: 566-572 (2000)

79.  Pinsky L, DiGeorge A.: Cleft palate in the mouse: A teratogenic index of glucocorticoid potency. Science 147: 402(1965)

80.  Brooks P.M., Needs C.J.: Antirheumatic drugs in pregnancy and lactation. Baillieres Clin. Rheumatol. 4: 157 (1990)

81.  Park-Wyllie L, Mazzotta P., Pastuszak A., Moretti M.E., Beique L, Hunnisett L, Friesen M.H., Jacobson S., Kasapinovic S., Chang D., Diav-Citrin O., Chitayat D., Nulman l., Einarson T.R., Koren G.: Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 62: 385-392 (2000)

82.  American College of Obstetrics and Gynecology: Vitamin A Supplementation During Pregnancy. Committee Opinion No. 157, September. 1995

83.  Rothman K.J., Moore L.L., Singer M.R. et al.: Teratogenicity of high vitamin A intake. N. Engl. J. Med. 1414-1415 (1995)

84.  Menard K.M.: Vitamin and mineral supplement prior to and during pregnancy. Obstet. Gynecol. Clin. North Am. 24: 479-498 (1997)

85.  Collins M.D., Mao G.E.: Teratology of retinoids. Annu. Rev. Pharmacol. Toxicol. 39: 399-430 (1999)

86.  Andermann S.: Anticonvulsants tied to congenital malformations. Presented at the American Academy of Neurology, San Francisco, 1996

87.  Brodie M.J., Dichter M.A.: Antiepileptic drugs. N. Engl. J. Med. 334: 168 (1996)

88.  Fonager K., Larsen H., Pedersen L, Sorensen H.T.: Birth outcomes in women exposed to anticonvulsant drugs. Acta Neurol. Scand. 101: 289-294 (2000)

89.  Kaneko S., Otani K., Fukushima Y., et al.: Teratogenicity of antiepileptic drugs: Analysis of possible risk factors. Epilepsia 29: 459 (1988)

90.  Koch S., Lösche G., Jager-Roman E., et al.: Major and minor birth malformation and antiepileptic drugs. Neurology 42(suppl): 83-88 (1992)

91.  Yerby M.S.: Epilepsy and Pregnancy. New issues for an old disorder. Neurol Clin. 11: 777-786 (1993)

92.  Hanson J.W., Smith D.W.: The fetal hydantoin syndrome. J. Pediatr. 87: 285-290 (1975)

93.  Gaily E., Granstrom M-L., Hiilesmaa V., et al.: Minor anomalies in offspring of epileptic mothers. J. Pediatr. 112: 520-529(1988)

94.  Jones K.L., Lacro R.V., Johnson K.A., et al.: Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl. J. Med. 329: 1661-1666 (1989)

95.  Lindhout D., Sshmidt D.: In utero exposure to valproate and neural tube defects. Lancet 2: 1392-1393 (1986)

96.  Rosa F.W.: Spina bifida in infants of women treated with carbamazepine during pregnancy. N. Engl. J. Med. 324: 674-677(1991)

97.  American College of Obstetricians and Gynecologists: Alpha-fetoprotein. Pp. 154, ACOG Technical Bulletin, 1991

98.  Freidman J.M., Polifka J.E.: The Effects of Drugs on the Fetus and Nursing Infant. The Johns Hopkins University Press, Baltimore, 1996

99.  Reinisch J.M., Sanders S.A., Mortensen E.L., et al.: In utero exposure to phénobarbital and intelligence deficits in adult men. JAMA 274: 1518-1525 (1995)

100. American College of Obstetricians and Gynecologists: Seizure disorders in pregnancy. P. 231, ACOG Educational Bulletin, 1996

101. Arpino C., Brescianini S., Robert E., Castilla E.E., Cocchi G., Cornel M.C., de Vigan C., Lancaster P.A., Merlob P., Sumiyoshi Y., Zampino G., Renzi C., Rosano A., Mastroiacovo P.: Teratogenic effects of antiepileptic drugs: use of an international database on malformations and drug exposure. Epilepsia 41: 1436-1443 (2000)

102. Hvas C.L., Henriksen T.B., Ostergaard J.R., Dam M.: Epilepsy and pregnancy: effect of antiepileptic drugs and lifestyle on birth weight. BJOG 107: 896-902 (2000)

103. Eller D.P., Patterson C.A., Webb G.W.: Maternal and fetal implications of anticonvulsive therapy during pregnancy. Obstet. Gynecol. Clin. North Am. 24: 523-534 (1997)

104. Samuels P.: Neurologicdisorders. In (Gabbe S., Niebyl J., Simpson J.L., eds), Obstetrics: Normal and Problem Pregnancies. 3^rd ed. Pp. 1135-1144, WB Saunders, Philadelphia, 1996

105. Diket A., Nolan T.: Anxiety and Depression: Diagnosis and Treatment During Pregnancy. Obstet. Gynecol. Clin. North Am. 24: 535-556 (1997)

106. Weinstein M.R.: Lilhium treatment of women during pregnancy and in postdelivery period. In: (Johnson F.N. ed.) Handbook of Lithium Therapy. Pp. 421-429, University Park Press, Baltimore, MD, 1980

107. Schou M.: [50 years lithium treatment]. Encéphale 26(2): 1-6 (2000)

108. Pastuszak A., Schick-Boschetto B., Zuber C., et al.: Pregnancy outcomes following first-trimester exposure to fluoxetine (Prozac). JAMA 269: 2246-2248 (1993)

109. Chambers C.A., Johnson K.A., Dick L.M., et al.: Birth outcomes in pregnant women taking fluoxetine. N. Engl. J. Med. 335: 1010-1015 (1996)

110. Ecker J.L., Musci T.J.: Treatment of thyroid disease in pregnancy. Obst. Gynecol. Clin. North Am. 24: 575-589 (1997)

111. Wing D.A., Millar L.K., Koonings P.P., et al.: A comparison of propylthiouracil versus methimazole in the treatment of hyperthyroidism in pregnancy. Am. J. Obstet. Gynecol. 170: 90-95 (1994)

112. Atkins P., Cohen S.B., Phillips B.J.: Drug therapy for hyperthyroidism in pregnancy: safety issues for mother and fetus. Drug Saf. 20: 229-244 (2000)

113. Milham S.: Scalp defects in infants of mothers treated for hyperthyroidism with methimazole or carbimazole during pregnancy. Teratology 32: 321 (1985)

114. Momotani N., Noh J., Oyanagi H., et at.: Antithyroid drug therapy for Graves’ disease during pregnancy. N. Engl. J. Med. 315: 24 (1986)

115. Van Dijke C.P., Heyendael R.S., De Kleine M.J.: Methimazoie, carbimazole and congenital skin defects. Ann. Intern. Med. 106: 60-61 (1987)

116. Koutras D.A.: Thyroidopathies. Ann. N. Y. Acad. Sci. 900: 77-88 (2000)

11. Born D., Martinez E.E., Almeida P.A.M., et al.: Pregnancy in patients with prosthetic heart valves: The effects of anticoagulation on mother, fetus, neonate. Am. Heart J. 124: 413-417 (1992)

118. Sbarouni E., Oakley C.: Outcome of pregnancy in women with valve prostheses. Br. Heart J. 71: 196-201 (1994)

119. Vitali E., Donateli F., Quaini E., et al.: Pregnancy in patients with mechanical prosthetic heart valve: Our experiences regarding 98 pregnancies in 57 patients. J. Cardiovasc. Surg. 27: 221-227 (1986)

120. Barbour L.A.: Current concepts of anticoagulant therapy in pregnancy. Obst. Gynecol. Clin. North Am. 24: 499- 521 (1997)

121. Ginsberg J.S., Hirsch J., Turner D.C., et al.: Risks to the fetus of anticoagulant therapy during pregnancy, Thromb. Haemost. 61: 197-203 (1989)

122. Ginsberg J.S., Kowalchuk G., Hirsch J., et at.: Heparin therapy during pregnancy: Risks to the fetus and mother. Arch. Intern. Med. 140: 2233-2236 (1989)

123. Sorensen H.T., Johnsen S.P., Larsen H., Pedersen L., Nielsen G.L., Möller M.: Birth outcomes in pregnant women treated with low-molecular-weight heparin. Acta Obstet. Gynecol. Scand. 70: 655-659 (2000)

124. Rubin P.: Treatment of Hypertension in Pregnancy. Clin. Obstet. Gynaecol. 10: 307-317 (1986)

125. Khedun S.M., Maharaj B., Moodley J.: Effects of antihypertensive drugs on the unborn child: what is known, and how should this influence prescribing? Paediatr. Drugs 2: 419-436 (2000)

126. Magee L.A., Duley L.: Oral beta-blockers for mild to moderate hypertension during pregnancy (Cochrane Review). Cochrane Database Syst. Rev. 4: CD002863 (2000)

127. Beeley L.: Adverse effects of drugs in the first trimester of pregnancy. Clin. Obstet. Gynaecol. 10: 177-186 (1986)

128. Schardein J.L.: Congenital abnormalities and hormones during pregnancy: a clinical review. Teratology 22: 251-270(1980)

129. Wilson J.G., Brent R.L.: Are female sex hormones teratogenic? Am. J. Obstet. Gynecol. 141: 567-580 (1981)

130. Harlap S., Eldor J.: Births following oral contaceptive failure. Obstet. Gynecol. 55: 447-452 (1980)

131. Jefferies J.A., Robboy S.J., O’Brien P.C., et al.: Structural abnormalities of the cervix and vagina in women enrolled in the diethylstilboestrol (DESAD) project. Am. J. Obstet. Gynecol. 148: 59-66 (1984)

132. Harvey R., Champe P., et al.: Pharmacology: Lippincott’s Illustrated Reviews. Pp. 91-95, 101-104, J. B. Lippincott Company, Philadelphia, 1992

133. Κοκκέβη A., Στεφάνής К.: Τα ναρκωτικά στην Ελλάδα: Η διαχρονική πορεία της χρήσης, Ερευνητικό Πανεπιστημιακό Ινστιτούτο Ψυχικής Υγιεινής, Αθήνα: 71-78, 191- 197 (1994)

134. Aarskog D.: Association between maternal intake of diazepam and oral clefts. Lancet 2: 29 (1975)

135. Safra M.J., Oakley G.P.: An association between cleft lip with or without cleft palate and prenatal exposure to valium. Lancet 2: 478-479 (1975)

136. Saxen I.: Epidemiology of cleft lip and palate. Br. J. Prevent. Soc. Med. 29: 103-110 (1975)

137. Rosenburg L, Mitchell A.A., Parsells J.L, et al.: Lack of correlation of oral clefts to diazepam use in pregnancy. N Engl. J. Med. 300: 1282-1285 (1983)

138. Czeizel A.: Lack of evidence of teratogenicity of benzodiazepine drugs in Hungary. Reprod. Toxicol. 1: 183-189 (1988)

139. Shiono P.H., Mills J.L.: Oral clefts and diazepam use during pregnancy. N. Engl. J. Med. 311: 919-920 (1984)

140. Bracken M.B.: Drug use in pregnancy and congenital heart disease in offspring. N. Engl. J. Med. 314: 1120 (1986)

141. Zierler S., Rothman K.J.: Congenital heart disease in relation to maternal use of Bendectin and other drugs in early pregnancy. N. Engl. J. Med. 313: 347-352 (1985)

142. Gillberg C.: “Floppy infant syndrome” and maternal diazepam. Lancet 2: 244 (1977)

143. Rementeria J.L., Bhatt K.: Withdrawal symptoms in neonates from intrauterine exposure to diazepam. J. Pediatr. 90: 123-126(1977)

144. Anderson P.O., Mcguire G.G.: Neonatal withdrawal – possible effects of breast feeding. Drug Intelligence and Clinical Pharmacy – Annals Pharmacother. 23: 614 (1989)

145. Barry W.S., St. Clair S.M.: Exposure to benzodiazepines in utero. Lancet 1: 1436-1437 (1987)

146. Deltsidou A., Lykeridou K., Plessas S.: Congenital anomalies and aetiology. Epith. Klin. Farmakol. Farmakokinet. (International Edition) 14: 111-115 (2000)

147. Δελτσίδου A., Λυκερίδου К., Πλέσσας Σ.: Μεταφορά φαρμάκων δια μέσου του πλακούντα. Επιθ. Κλιν. Φαρμακ. Φαρμακοκ. 18: 173-180 (2000)

148. Deltsidou A., Lykeridou К., Plessas S.: Licit substance abuse during pregnancy and its effects on the fetus. Epitheor. Klin. Farmakol. Farmakokinet. Intern. Ed. 15: 21-32 (2001)

pharmakonpress[at]pharmakonpress[.]gr

pharmakonpress[at]pharmakonpress[.]gr